Our Pricing

Mounjaro vs Wegovy: Your Complete Starter Dose Guide

Understanding the mounjaro vs wegovy starter dose UK differences is essential when beginning your weight loss journey. Both medications follow structured dose escalation schedules designed by their manufacturers to minimise side effects whilst maximising efficacy, but the titration pathways differ significantly. At Cured Pharmacy, our UK-registered clinical team guides patients through both options with transparent pricing and expert support.

Wegovy Starter Dose: The Semaglutide Escalation Schedule

Wegovy's starter dose begins at 0.25mg once weekly for the first four weeks [1]. This low initial dose allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation, reducing the likelihood of nausea and gastrointestinal discomfort that can occur when GLP-1 receptor agonists are introduced too quickly.

The full Wegovy dose escalation follows a five-step titration over 16 weeks: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally the maintenance dose of 2.4mg from week 17 onwards [1]. Each increment is designed to build therapeutic efficacy whilst maintaining tolerability, with clinical trials showing that patients who followed this gradual schedule experienced fewer treatment discontinuations due to side effects.

In the STEP 1 trial, participants following this exact dosing schedule achieved an average 14.9% body weight reduction over 68 weeks, with 86.4% of patients able to complete the full titration to the 2.4mg maintenance dose [1]. The structured approach allows your UK prescriber to monitor your response at each stage and adjust timing if needed, though most patients progress according to the standard schedule.

Mounjaro Starter Dose: The Tirzepatide Titration Pathway

Mounjaro's starter dose is 2.5mg once weekly for the first four weeks [2]. This represents a different approach to dose initiation compared to Wegovy, reflecting tirzepatide's dual GIP/GLP-1 receptor mechanism and its distinct pharmacological profile. The higher starting dose is still carefully calibrated to minimise gastrointestinal side effects whilst establishing therapeutic levels more quickly.

The complete Mounjaro escalation schedule progresses through six possible dose levels: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 7.5mg (weeks 9-12), 10mg (weeks 13-16), 12.5mg (weeks 17-20), and up to 15mg as the maximum maintenance dose from week 21 onwards [2]. Not all patients require the highest dose—your UK prescriber will determine your optimal maintenance level based on weight loss response and tolerability, with many patients achieving excellent results at the 10mg or 12.5mg doses.

In the SURMOUNT-1 trial, patients on the 15mg maintenance dose achieved an average 20.9% body weight reduction over 72 weeks, whilst those on 10mg achieved 19.5% reduction [2]. The tirzepatide dosing schedule allows for more granular dose optimisation compared to semaglutide, giving prescribers additional flexibility to balance efficacy and side effects for individual patients.

Key Differences in Starter Dose Philosophy

The fundamental difference between these starter doses reflects each medication's mechanism and potency profile. Wegovy begins at 0.25mg because semaglutide's selective GLP-1 receptor activation requires a gentler introduction, whilst Mounjaro's 2.5mg starting point leverages tirzepatide's dual receptor activity with a dosing schedule designed around its specific pharmacokinetics. Both approaches are evidence-based and MHRA-approved, with the 'right' choice depending on your individual clinical profile and prescriber assessment.

Mounjaro vs Wegovy Starter Dose UK: Side Effects During Titration

During the starter dose phase, both medications commonly cause mild to moderate gastrointestinal effects as your body adapts to altered gastric emptying and appetite signalling [1][2]. With Wegovy's 0.25mg starter dose, approximately 44% of patients in clinical trials reported nausea during the first month, though this typically diminished as titration progressed and rarely led to treatment discontinuation when the escalation schedule was followed properly.

Mounjaro's 2.5mg starter dose produced similar gastrointestinal effects, with nausea reported in approximately 33% of patients during the initial four weeks in the SURMOUNT trials [2]. Other common starter dose side effects for both medications include diarrhoea, constipation, abdominal discomfort, and reduced appetite—effects that are generally transient and improve as your body adjusts to each new dose level.

The structured dose escalation schedules for both medications exist specifically to minimise these side effects. Patients who attempt to increase doses too quickly or skip titration steps experience significantly higher rates of gastrointestinal distress and treatment discontinuation. Your UK prescriber at Cured Pharmacy will provide detailed guidance on managing starter dose side effects, including dietary modifications, hydration strategies, and when to consider delaying dose escalation if symptoms are particularly troublesome.

Managing Starter Dose Symptoms

Practical strategies can significantly reduce starter dose discomfort for both medications. Eating smaller, more frequent meals rather than large portions, avoiding high-fat foods that slow gastric emptying further, staying well-hydrated, and injecting at consistent times each week all help your body adapt more comfortably. If nausea persists beyond the first few weeks at any dose level, speak with your prescriber before your next scheduled increase—extending a dose phase by an additional four weeks is often preferable to discontinuing treatment entirely.

Comparing Efficacy: Does Starter Dose Predict Final Results?

The starter dose phase is not intended to produce significant weight loss—its purpose is physiological adaptation and tolerability assessment. Most patients experience minimal weight reduction during the first 4-8 weeks on either medication, with meaningful weight loss typically beginning as doses reach therapeutic levels in months 2-4 [1][2].

Head-to-head clinical data suggests that tirzepatide produces greater average weight loss than semaglutide at their respective maintenance doses. In the SURPASS-2 trial, which directly compared the two medications, tirzepatide 15mg resulted in superior weight reduction compared to semaglutide 1mg (approved for diabetes, not the 2.4mg Wegovy dose) [3]. Whilst no large-scale trial has directly compared Mounjaro 15mg to Wegovy 2.4mg in weight management populations, indirect comparisons of their pivotal trials suggest tirzepatide's dual receptor mechanism may offer an additional 5-7 percentage points of body weight reduction on average.

However, individual response varies considerably, and some patients achieve excellent results with Wegovy whilst tolerating it better than Mounjaro. The starter dose phase allows both you and your prescriber to assess not just tolerability but also early indicators of response—patients who experience significant appetite suppression and early weight loss during titration often achieve better long-term outcomes regardless of which medication they're prescribed.

Cost Considerations: Mounjaro vs Wegovy Starter Dose UK Pricing

At Cured Pharmacy, Wegovy is available from £79.00 per month, representing competitive UK pricing for this MHRA-licensed semaglutide treatment. The cost remains consistent throughout your dose escalation, as each monthly supply contains four pre-filled pens at your current dose level—whether you're on the 0.25mg starter dose or the 2.4mg maintenance dose.

Pricing structures for weight loss medications in the UK market vary by pharmacy and dose level, though licensed online pharmacies typically offer more competitive rates than high-street alternatives. All prescription weight loss treatments at Cured Pharmacy require a free online clinical consultation with a UK-registered prescriber, ensuring you receive appropriate assessment regardless of which medication you choose.

When comparing total treatment costs, consider that both medications require several months of dose escalation before reaching maintenance levels, meaning you'll need multiple months of supply to complete titration and assess full efficacy. Most patients remain on these treatments for 12-18 months to achieve and consolidate their weight loss goals, making long-term affordability and consistent supply an important consideration when choosing between Mounjaro and Wegovy.

Transparent Pricing at Cured Pharmacy

Unlike some online pharmacies that hide pricing until after consultation, Cured Pharmacy displays all treatment costs upfront before you begin your clinical assessment. This transparency allows you to make informed decisions about which treatment fits your budget, with no hidden fees or surprise charges. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all pricing remains competitive whilst maintaining the highest standards of pharmaceutical care and genuine UK-licensed medications.

Starting Your Treatment: Next Steps at Cured Pharmacy

Beginning either Wegovy or Mounjaro requires a clinical consultation with a UK-registered prescriber, which takes under three minutes to complete online at Cured Pharmacy. The assessment covers your medical history, current medications, weight loss goals, previous diet and exercise attempts, and any contraindications to GLP-1 receptor agonist therapy. This ensures the prescribed treatment is both safe and appropriate for your individual circumstances.

If approved, your prescription is reviewed by our UK-registered clinical team and dispensed from our GPhC-registered pharmacy (registration number 9012511). All medications are genuine UK-licensed products supplied in discreet packaging with full patient information leaflets and injection technique guidance. First-time users receive detailed instructions on subcutaneous injection technique, pen operation, and proper storage requirements.

Your treatment arrives with clear starter dose instructions specific to your prescribed medication. For Wegovy, you'll begin with the 0.25mg dose for four weeks before progressing to 0.5mg; for Mounjaro, you'll start at 2.5mg for the first month before increasing to 5mg. Follow-up consultations allow your prescriber to monitor progress, adjust dosing schedules if needed, and address any concerns during your titration phase. Most patients find the injection process straightforward after the first few doses, with once-weekly administration fitting easily into their routine.

What to Expect During Your First Month

The first four weeks on either starter dose focus on adaptation rather than dramatic weight loss. You'll likely notice reduced appetite and earlier satiety when eating, with gradual weight reduction beginning as your body adjusts to the medication. Mild gastrointestinal effects are common but typically manageable with dietary adjustments. Keep a simple log of your weekly weight, any side effects, and how you're tolerating the medication—this information helps your prescriber optimise your treatment plan as you progress through dose escalation. Remember that weight loss medications work best alongside sustainable lifestyle modifications, including balanced nutrition and regular physical activity appropriate to your fitness level.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
3. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, lifestyle modifications, and individual metabolic response. Clinical trial data represents average outcomes and does not guarantee specific results for any individual patient.